Cancer Blog
- Dr. Robert Nagourney -

Dr. Robert A. Nagourney, MD

Hitting Cancer True and Straight: the Role of Tissue Analysis

Although she showed some response, her disease persisted and she was being considered for surgery to remove the residual tumor...

Dr. Robert A. Nagourney, MD

Recurrent Lung Cancer Patients Need To “Get Down On It”

George Brown is alive today because our laboratory analysis identified a simple 2 drug combination that now one else thought to give him.

Dr. Robert A. Nagourney, MD

A Triple Negative Breast Cancer Patient's Journey: Going the Extra Mile

This patient had recurrent breast cancer that upon biopsy proved to be triple negative.

Dr. Robert A. Nagourney, MD

Your Cancer Cure May Already Exist

Personalized treatment means more cured patients. More people survive cancer when our Functional Profiling system is used before treatment.

Dr. Robert A. Nagourney, MD

Pancreatic Cancer Surgery: Know What You Have Consented To!

However, a new dilemma has arisen; the failure of surgeons to comply with Pancreatic Cancer patient’s wishes to have tissue submitted.

Dr. Robert A. Nagourney, MD

Stage 4 Cancer Patient Survivals: The Data Is In and It’s Not Good

There has been talk of improved survival in cancer, most progress has reflected screening, early diagnosis, improved staging, and support.

Dr. Robert A. Nagourney, MD

Challenging Paradigms: The Management of Rectal Cancer

One noteworthy case was a 78-year-old patient successfully treated without surgery.

Dr. Robert A. Nagourney, MD

Breakthrough for Young Patients with a Rare Form of Liver Cancer

Extremely rare liver cancer that mostly affects people in their twenties associated with a gene rearrangement, mostly lethal, until now.

Dr. Robert A. Nagourney, MD

For Medical Oncology, Déjà Vu All Over Again

Patients are being encouraged to contact the researchers to get biopsies and help take charge of their disease.

Dr. Robert A. Nagourney, MD

Nagourney Cancer Institute: 20-year Experience in 10,000 Patients

At the 2023 American Association for Cancer Research meeting in Orlando, we reported results of ex vivo analysis of programmed cell death.

Dr. Robert A. Nagourney, MD

A Year-End Reflection

2022 Reflection. Among our most important accomplishments in 2022 was the installation of a world-class Mass Spectrometry research program.